

LEVARIS

FOR IMMEDIATE RELEASE

World Reach Health Rebrands to Levaris, Signaling a New Era of Institutional Stewardship in Healthcare

HOLLYWOOD, Fla. — July 23, 2026 — Levaris, an institutional healthcare platform, today announced its official rebranding from World Reach Health. Moving beyond its origin as a holding entity, Levaris provides the accountable governance and patient capital required to scale breakthrough technologies in an era of outcomes accountability.

"Levaris represents clarity and discipline in an increasingly complex healthcare landscape," said Levaris CEO Jelena Olmstead. "We are building an institutional platform grounded in science, ethics, and patient dignity — ensuring clinical excellence remains at the forefront, regardless of market dynamics."

Furthering this mission, Levaris is co-sponsoring a legislative bill with the office of Congressman Pete Sessions and other congressional leaders. The legislation aims to expand access for underserved chronic wound patients while establishing new national benchmarks for care quality and patient outcomes.

The Levaris model is currently demonstrated through **DermaBind**, a dehydrated, full-thickness placental membrane for hard-to-heal wounds. Utilizing a proprietary preservation method that retains all native layers of the human placenta, this 1000-micron allograft preserves a matrix of 400+ proteins engineered for complex, comorbid patients.

DermaBind's evidence-based approach, anchored by its **Clinical Stewardship Program**, provides practitioners with the clinical precision and regulatory safety required to thrive as the industry moves away from reimbursement arbitrage.

ABOUT LEVARIS

Levaris is an institutional healthcare platform committed to delivering the best possible outcomes. As a learning organization, Levaris provides stable governance and long-term capital to nurture technologies from proof-of-concept to full market potential across multiple medical categories. Learn more at www.levarisglobal.com.

ABOUT DERMABIND

DermaBind, a Levaris company, is the gold standard in advanced wound care. Its 3-layer intact placental allograft is engineered for complex patients, with clinical data showing a 69.1% average wound surface area reduction in recent case studies. Its Clinical Stewardship Program reduces regulatory risk and prioritizes patient dignity. Learn more at www.dermabind.com.

Media Contact: Teddy Flores | teddy@levarisglobal.com

2950 N 28th Terrace Hollywood,
FL 33020, United States

levarisglobal.com